Center for Integrated Protein Science at the Department Chemie, Lehrstuhl für Biochemie, TU München (Germany).
Angew Chem Int Ed Engl. 2014 Feb 3;53(6):1679-83. doi: 10.1002/anie.201308984. Epub 2014 Jan 8.
The ubiquitin-proteasome system (UPS) has been successfully targeted by both academia and the pharmaceutical industry for oncological and immunological applications. Typical proteasome inhibitors are based on a peptidic backbone endowed with an electrophilic C-terminus by which they react with the active proteolytic sites. Although the peptide moiety has attracted much attention in terms of subunit selectivity, the target specificity and biological stability of the compounds are largely determined by the reactive warheads. In this study, we have carried out a systematic investigation of described electrophiles by a combination of in vitro, in vivo, and structural methods in order to disclose the implications of altered functionality and chemical reactivity. Thereby, we were able to introduce and characterize the class of α-ketoamides as the most potent reversible inhibitors with possible applications for the therapy of solid tumors as well as autoimmune disorders.
泛素-蛋白酶体系统 (UPS) 已成为学术界和制药行业的研究热点,可用于治疗肿瘤和免疫相关疾病。典型的蛋白酶体抑制剂基于具有亲电 C 末端的肽骨架,通过该 C 末端与蛋白酶的活性位点发生反应。尽管肽段在亚基选择性方面引起了广泛关注,但化合物的靶标特异性和生物稳定性在很大程度上取决于反应性弹头。在这项研究中,我们结合了体外、体内和结构方法对已报道的亲电试剂进行了系统研究,以揭示功能改变和化学反应性的影响。由此,我们成功引入并表征了α-酮酰胺类化合物,其作为最有效的可逆抑制剂,可能在治疗实体瘤和自身免疫性疾病方面具有应用前景。